Figure 4.

Cost analysis for applying enrichment to GRIPHON (Selexipag in Pulmonary Arterial Hypertension). Each enrichment strategy was applied to GRIPHON, and estimated ratios of total cost of screening versus total cost of conducting trial (i.e., research cost) as well as net savings as a percentage of the cost of a nonenriched trial were calculated. Cost of screening and cost of research were estimated per Table 3. COMPERA = Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension; French = French score; REVEAL = Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management.